ProQR Therapeutics (PRQR) News Today $1.86 -0.14 (-6.78%) As of 01:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Equities Analysts Set Expectations for PRQR FY2025 EarningsProQR Therapeutics (NASDAQ:PRQR - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for ProQR Therapeutics in a research note issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the biopharmaceutical company will post earnings per shaMay 3 at 8:11 AM | marketbeat.comProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on ThursdayProQR Therapeutics (NASDAQ:PRQR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-proqr-therapeutics-stock/)May 3 at 5:31 AM | marketbeat.comCantor Fitzgerald Weighs in on PRQR FY2025 EarningsMay 3 at 2:51 AM | americanbankingnews.comProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences ConferenceMay 2 at 8:00 AM | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by Boothbay Fund Management LLCBoothbay Fund Management LLC increased its holdings in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 143.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 260,276 shares of the biopharmaceutical company's stockMay 2 at 5:12 AM | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Now Covered by Cantor FitzgeraldCantor Fitzgerald started coverage on ProQR Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $8.00 target price for the company.May 1, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Evercore ISIEvercore ISI initiated coverage on shares of ProQR Therapeutics in a report on Tuesday. They set an "outperform" rating and a $5.00 target price for the company.May 1, 2025 | marketbeat.comProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025May 1, 2025 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Evercore ISIMay 1, 2025 | americanbankingnews.comProQR Therapeutics initiated with an Outperform at Evercore ISIApril 30, 2025 | finance.yahoo.comEvercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform RecommendationApril 30, 2025 | msn.comProQR Therapeutics assumed with an Overweight at Cantor FitzgeraldApril 29, 2025 | finance.yahoo.comProQR Therapeutics (NASDAQ:PRQR) Stock Position Boosted by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. grew its stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 164.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,602,280 shares of the biopharmaceuticApril 28, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Sees Significant Decline in Short InterestProQR Therapeutics (NASDAQ:PRQR - Get Free Report) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 843,100 shares, a drop of 17.3% from the March 15th total of 1,020,000 shares. Based on an average daily trading volume, of 476,600 shares, the short-interest ratio is currently 1.8 days. Approximately 1.1% of the company's stock are sold short.April 22, 2025 | marketbeat.comWalleye Capital LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR)Walleye Capital LLC acquired a new position in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 451,303 shares of the biopharmaceutical company's stock, valuedApril 22, 2025 | marketbeat.com575,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Altium Capital Management LLCAltium Capital Management LLC acquired a new stake in ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 575,000 shares of the biopharmaceutical company's stock, valApril 20, 2025 | marketbeat.com2,825,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Affinity Asset Advisors LLCAffinity Asset Advisors LLC bought a new stake in ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,825,000 shares of the biopharmaceutical company's stock, valued at approxiApril 17, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by BrokeragesShares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received a consensus rating of "Buy" from the six research firms that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a sApril 17, 2025 | marketbeat.comProQR Therapeutics appoints Hom as CFO, Lopez as CMOApril 14, 2025 | markets.businessinsider.comProQR Therapeutics N.V.: ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of GrowthApril 14, 2025 | finanznachrichten.deProQR Therapeutics Names Hom as CFO, Lopez Lopez as Chief Medical OfficerApril 14, 2025 | marketwatch.comProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of GrowthApril 14, 2025 | globenewswire.comProQR Therapeutics Advances RNA Editing PipelineApril 3, 2025 | tipranks.comFY2025 Earnings Estimate for PRQR Issued By Chardan CapitalProQR Therapeutics (NASDAQ:PRQR - Free Report) - Research analysts at Chardan Capital raised their FY2025 earnings per share estimates for ProQR Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the biopharmaMarch 28, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by BrokeragesProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are currently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating tMarch 22, 2025 | marketbeat.comPrivium Fund Management B.V. Decreases Stake in ProQR Therapeutics (NASDAQ:PRQR)Privium Fund Management B.V. reduced its position in ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 11.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,985,633 shares of the biopharmaceutical company's stock after selMarch 20, 2025 | marketbeat.comPlatinum Investment Management Ltd. Purchases Shares of 1,538,247 ProQR Therapeutics (NASDAQ:PRQR)Platinum Investment Management Ltd. purchased a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,538,247 shares of the biopharmaceutical company's stMarch 20, 2025 | marketbeat.comProQR Therapeutics Full Year 2024 Earnings: Misses ExpectationsMarch 15, 2025 | uk.finance.yahoo.comProQR Therapeutics' (PRQR) Buy Rating Reiterated at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday.March 15, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $12.00HC Wainwright lifted their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday.March 15, 2025 | marketbeat.comProQR Therapeutics price target raised to $12 from $10 at H.C. WainwrightMarch 14, 2025 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Announces Earnings ResultsProQR Therapeutics (NASDAQ:PRQR - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%.March 14, 2025 | marketbeat.comProQR Therapeutics N.V.: ProQR Announces Year End 2024 Operating and Financial ResultsMarch 14, 2025 | finanznachrichten.deProQR Therapeutics files to sell 3.52M ordinary shares for holdersMarch 14, 2025 | markets.businessinsider.comProQR Therapeutics Reports 2024 Results and Pipeline ProgressMarch 13, 2025 | tipranks.comProQR Announces Year End 2024 Operating and Financial ResultsMarch 13, 2025 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by CitigroupCitigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target for the company in a research note on Monday.March 10, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Buy at CitigroupCitigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price on the stock in a research report on Monday.March 10, 2025 | marketbeat.comProQR Therapeutics upgraded to Buy from Neutral at CitiMarch 7, 2025 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average - Here's What HappenedProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?March 5, 2025 | marketbeat.comProQR Therapeutics (PRQR) Expected to Announce Earnings on WednesdayProQR Therapeutics (NASDAQ:PRQR) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from BrokeragesShares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received an average rating of "Buy" from the six analysts that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation oFebruary 25, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50 Day Moving Average - Here's WhyFebruary 20, 2025 | marketbeat.comJones Trading Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Buy RecommendationFebruary 12, 2025 | msn.comJones Trading sets ProQR stock Buy rating, $11 price targetFebruary 11, 2025 | msn.comProQR Therapeutics initiated with a Buy at JonesResearchFebruary 11, 2025 | markets.businessinsider.comProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17%February 11, 2025 | finance.yahoo.comProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of "Buy" by BrokeragesShares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buyJanuary 31, 2025 | marketbeat.comCantor Fitzgerald Predicts PRQR FY2025 EarningsProQR Therapeutics (NASDAQ:PRQR - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ProQR Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim expects that the biopharmaceutiJanuary 22, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Short Interest UpdateProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 918,100 shares, an increase of 151.7% from the December 15th total of 364,700 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is currently 0.6 days.January 14, 2025 | marketbeat.com Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address PRQR Media Mentions By Week PRQR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼0.680.72▲Average Medical News Sentiment PRQR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼172▲PRQR Articles Average Week Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KalVista Pharmaceuticals News Today Arbutus Biopharma News Today Trevi Therapeutics News Today ChromaDex News Today Pharming Group News Today Organogenesis News Today CorMedix News Today Bicycle Therapeutics News Today Immatics News Today Keros Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRQR Stock Free PRQR Stock Alerts